Antithrombotic therapy in coronary artery disease patients with atrial fibrillation

Table 2 The incidence of major adverse outcomes during follow-up

	n (%)	OAC	SAPT	DAPT	DT	TT	P-value
Ischemic stroke	23 (1.12)	4 (0.20)	12 (0.59)	6 (0.29)	1 (0.05)	0 (0)
SCAD+AF	7 (1.25)	1 (0.18)	4 (0.72)	2 (0.36)	0 (0)	0 (0)
ACS + AF	16 (1.07)	3 (0.20)	8 (0.54)	4 (0.27)	1 (0.07)	0 (0)	0.732
Bleeding	93 (4.54)	14 (0.68)	7 (0.34)	20 (0.05)	23 (1.12)	29 (1.41)
SCAD+AF	13 (2.33)	5 (0.89)	2 (0.36)	1 (0.18)	1 (0.18)	4 (0.72)
ACS + AF	80 (5.37)	9 (0.60)	5 (0.34)	19 (1.27)	22 (1.48)	25 (1.68)	0.003*
mild bleeding	59 (2.88)	11 (0.54)	6 (0.29)	12 (0.59)	16 (0.78)	14 (0.68)
SCAD+AF	9 (1.61)	4 (0.72)	2 (0.36)	0 (0)	1 (0.18)	2 (0.36)
ACS + AF	50 (3.35)	7 (0.47)	4 (0.27)	12 (0.80)	15 (1.01)	12 (0.80)	0.035*
moderate bleeding	29 (1.41)	3 (0.15)	1 (0.05)	7 (0.34)	6 (0.29)	12 (0.59)
SCAD+AF	3 (0.54)	1 (0.18)	0 (0)	1 (0.18)	0 (0)	1 (0.18)
ACS + AF	26 (1.74)	2 (0.13)	1 (0.07)	6 (0.40)	6 (0.40)	11 (0.74)	0.039*
major bleeding	5 (0.24)	0 (0)	0 (0)	1 (0.05)	1 (0.05)	3 (0.15)
SCAD+AF	1 (0.18)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.18)
ACS + AF	4 (0.27)	0 (0)	0 (0)	1 (0.07)	1 (0.07)	2 (0.13)	1.000
MI	19 (0.93)	7 (0.34)	5 (0.24)	2 (0.10)	3 (0.15)	2 (0.10)
SCAD+AF	4 (0.72)	2 (0.36)	2 (0.36)	0 (0)	0 (0)	0 (0)
ACS + AF	15 (1.01)	5 (0.34)	3 (0.20)	2 (0.13)	3 (0.20)	2 (0.13)	0.725
All-cause death	39 (1.90)	11 (0.54)	8 (0.39)	7 (0.34)	4 (0.20)	9 (0.44)
SCAD+AF	5 (0.89)	1 (0.18)	2 (0.36)	0 (0.00)	1 (0.18)	1 (0.18)
ACS + AF	34 (2.28)	10 (0.67)	6 (0.40)	7 (0.47)	3 (0.20)	8 (0.54)	0.041*

*Statically significant at p < 0.05. Abbreviations: SCAD stable coronary artery disease, ACS acute coronary syndrome, AF atrial fibrillation, MI myocardial infarction, OAC oral anticoagulant, SAPT single antiplatelet therapy, DAPT double antiplatelet therapy, DT dual therapy, TT triple therapy

ISSN: 1471-2261